Results 41 to 50 of about 347,060 (291)

Advancements in DNA vaccine vectors, non-mechanical delivery methods, and molecular adjuvants to increase immunogenicity

Human Vaccines & Immunotherapeutics, 2017
A major advantage of DNA vaccination is the ability to induce both humoral and cellular immune responses. DNA vaccines are currently used in veterinary medicine, but have not achieved widespread acceptance for use in humans due to their low ...
John J. Suschak, James A. Williams, Connie S. Schmaljohn   +2 more
doaj   +1 more source

Novel enzymatic DNA produced from a text file achieves comparable immune responses as plasmid vaccine

npj Vaccines
DNA vaccines have garnered considerable attention due to their recent success in humans for SARS-CoV-2 and immunotherapy for cancer. However, conventional methods for creating and manufacturing DNA vaccines at-scale are slow and rate-limiting for timely ...
James Fuller, Erik Kvam, Sandrine Creton, Courtney Hall, Nicholas J. Tursi, Kerry Blatney, Rebecca Ryan, Xavier Godron, David B. Weiner, Winston Timp, Weston Griffin, John Nelson, Deborah H. Fuller   +12 more
doaj   +1 more source

Combinatorial peptide-based epitope mapping from Ebola virus DNA vaccines and infections reveals residue-level determinants of antibody binding

Human Vaccines & Immunotherapeutics, 2017
Ebola virus (EBOV) infection is highly lethal and results in severe febrile bleeding disorders that affect humans and non-human primates. One of the therapeutic approaches for treating EBOV infection focus largely on cocktails of monoclonal antibodies ...
Daniel R. Ripoll, Daniel A. J. Mitchell, Lesley C. Dupuy, Anders Wallqvist, Connie Schmaljohn, Sidhartha Chaudhury   +5 more
doaj   +1 more source

Calibrating models in economic evaluation: a comparison of alternative measures of goodness of fit, parameter search strategies and convergence criteria.

, 2011
BACKGROUND: The importance of assessing the accuracy of health economic decision models is widely recognized. Many applied decision models (implicitly) assume that the process of identifying relevant values for a model's input parameters is sufficient to
Karnon, Jonathan, Vanni, Tazio
core   +1 more source

Vaccines against toxoplasma gondii : challenges and opportunities [PDF]

, 2009
Development of vaccines against Toxoplasma gondii infection in humans is of high priority, given the high burden of disease in some areas of the world like South America, and the lack of effective drugs with few adverse effects.
Aliberti J, Angus CW, Aosai F, Aosai F, Awan KJ, Beghetto E, Bommireddy R, Bonenfant C, Boyle JP, Brinkmann V, Buxton D, Bülow R, Caetano BC, Conacher M, Cong H, Cong H, Constant SL, Couper KN, Craig W Roberts, Cui YL, Cuppari AF, Curtsinger JM, Curtsinger JM, Cutchins EC, Darcy F, Dautu G, Debard N, Debierre-Grockiego F, DeGregorio E, Denkers EY, Desolme B, Duquesne V, Echeverria PC, Elisabeth Förster-Waldl, Erik Jongert, Escajadillo A, Eskild Petersen, Fachado A, Fachado A, Flori P, Fox B, Frenkel JK, Garcia JL, Garcia JL, Gatkowska J, Gazzinelli R, Gazzinelli RT, Golkar M, Hakim FT, Igarashi M, Innes EA, Ishii K, Ishii KJ, Ismael AB, Ismael AB, Johnson LL, Jongert E, Jongert E, Jongert E, Kasper LH, Khan IA, Kijlstra A, Kodjikian L, Krahenbuhl JL, Kringel H, Letscher-Bru V, Letscher-Bru V, Leyva R, Lindsay DS, Liu Q, Lourenco EV, Lourenço EV, Martin V, McLeod R, Mishima M, Mishima M, Mohamed RM, Mévélec MN, Mévélec MN, Nicola Gargano, Nielsen HV, Nielsen HV, Petersen E, Petrovsky N, Pettersen EK, Pfefferkorn ER, Qu D, Reikvam A, Roque-Resendiz JL, Sabin AB, Sayles PC, Schaap D, Scorza T, Siachoque H, Sibley LD, Silveira C, Stanley AC, Stockinger B, Supply P, Taneja V, Vandepapelierea P, Velge-Roussel F, Velge-Roussel F, Vercammen M, Vogel N, Vyas JM, Waldeland H, Wang H, Wilkins MF, Williams MA, Xue M, Xue M, Yang CD, Yarovinsky F, Zenner L, Zhang G, Zhang J, Zimmermann S   +117 more
core   +3 more sources

Inhibition of CDK9 enhances AML cell death induced by combined venetoclax and azacitidine

Molecular Oncology, EarlyView.
The CDK9 inhibitor AZD4573 downregulates c‐MYC and MCL‐1 to induce death of cytarabine (AraC)‐resistant AML cells. This enhances VEN + AZA‐induced cell death significantly more than any combination of two of the three drugs in AraC‐resistant AML cells.
Shuangshuang Wu, Jianlei Zhao, Aaban Asfar Azmi, Avanti Gupte, Jenna Thibodeau, Shuang Liu, Jinli Yang, Guan Wang, Holly Edwards, Lisa A. Polin, Juiwanna Kushner, Sijana H. Dzinic, Kathryn White, Julie Boerner, Maik Hüttemann, Jay Yang, Yue Wang, Jeffrey W. Taub, Yubin Ge   +18 more
wiley   +1 more source

Novel Approach in DNA vaccine development against porcine circovirus type 2

Theoretical and Applied Veterinary Medicine
Porcine circovirus type 2 (PCV2) is an important viral pathogen in pig populations. However, commercial vaccines cannot provide complete protection with induced humoral immunity only against disease development.
H. Wei, S. D. Lenz, R. M. Pogranichniy
doaj   +1 more source

Novel recombinant DNA vaccine candidates for human respiratory syncytial virus: Preclinical evaluation of immunogenicity and protection efficiency

Human Vaccines & Immunotherapeutics, 2017
The development of safe and potent vaccines for human respiratory syncytial virus (HRSV) is still a challenge for researchers worldwide. DNA-based immunization is currently a promising approach that has been used to generate human vaccines for different ...
Mohamed A. Farrag, Haitham M. Amer, Peter Öhlschläger, Maaweya E. Hamad, Fahad N. Almajhdi   +4 more
doaj   +1 more source

KITD816V+ systemic mastocytosis associated with KITD816V+ acute erythroid leukaemia: first case report with molecular evidence for same progenitor cell derivation [PDF]

, 2009
Toll-like receptor (TLR)-9 recognizes CpG motifs in microbial DNA. TLR9 signalling stimulates innate antimicrobial immunity and modulates adaptive immune responses including autoimmunity against chromatin, e.g., in systemic lupus erythematosus (SLE ...
H-P Horny, K K Reichard, K Sotlar, M K Foucar, S A McClintock-Treep   +4 more
core   +1 more source

Developing evidence‐based, cost‐effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities

Molecular Oncology, EarlyView.
The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.
Ulrik Ringborg, Joachim von Braun, Julio Celis, Anton Berns, Michael Baumann, Tit Albreht, Nancy Abou‐Zeid, Vanderlei Bagnato, Christian Brandts, Chien‐Jen Chen, Massimiliano di Pietro, Manjit Dosanjh, Thomas Dubois, Alexander Eggermont, Angelika Eggert, Ingemar Ernberg, Sara Faithfull, Johannes Förner, Stefan Fröhling, Manuel Heitor, Leroy Hood, Wei Jiang, Bengt Jönsson, Ravi Kannan, Maria Leptin, Su Li, Peter Lindgren, Douglas Lowy, Jun Ma, Alex Markham, Péter Nagy, Simon Oberst, M. Iqbal Parker, Danielle Rodin, Kevin Ryan, Joachim Schüz, Richard Sullivan, Josep Tabernero, Peter Turkson, Oliver Várhelyi, Harold Varmus, Chijie Wang, Elisabete Weiderpass, Nils Wilking   +43 more
wiley   +1 more source